Merck Beats Quarterly Estimates on Keytruda Strength, Narrows 2025 Outlook

What happened

Merck posted first-quarter revenue of $16.29 billion, up 5% year-over-year and above Wall Street's $15.85 billion forecast. The beat was driven primarily by Keytruda, the company's cancer immunotherapy, which grew 12% in the period. The newly approved injection form of Keytruda, called Qlex, contributed $128 million in its first quarter on the market. Following the results, Merck narrowed its full-year sales guidance to $65.8 billion to $67 billion and raised the top end of its adjusted earnings forecast to $5.04 to $5.16 per share. On a GAAP basis, the company reported a loss of $1.72 per share due to a $3.62 per share charge related to its $9.2 billion acquisition of Cidara Therapeutics, completed in late 2024 to strengthen its respiratory drug portfolio.

Why the stock moved

Investors responded positively to Merck beating quarterly estimates and raising guidance, signaling confidence in the company's ability to sustain growth despite looming patent challenges. The strong Keytruda performance and early traction for Qlex suggest the company is successfully managing the transition ahead of the 2028 U.S. patent expiration. Additionally, CEO Rob Davis reinforced a disciplined approach to deals following the company's $6.7 billion acquisition of Terns Pharmaceuticals in March, which came in below initial bidding levels after Merck's due diligence revealed updated trial data. The combination of operational execution and strategic pipeline building appeared to reassure investors about life beyond Keytruda's patent cliff.

Bigger picture

Keytruda remains central to Merck's business, generating more than half of the company's pharmaceutical revenue. With patent protection ending in 2028, management has been clear that no single drug will replace Keytruda's contribution. Instead, the strategy relies on a portfolio approach combining newly launched products like Winrevair for blood pressure, Welireg for cancer, and Idvynso for HIV, alongside pipeline assets from acquisitions. The Terns deal for TERN-701, a chronic myeloid leukemia treatment, exemplifies this approach. While updated trial data showed the drug may be less differentiated than initially hoped, Merck's research chief Dean Li still views it as a meaningful advance over existing therapies. The company's willingness to walk away from inflated bids and negotiate a lower final price demonstrates a focus on value creation rather than blockbuster hunting.

What investors watch

The key metric to monitor is Keytruda's growth trajectory through 2028 and how quickly Qlex adoption offsets the eventual patent expiration. Investors should also track progress for pipeline candidates in lung cancer and influenza, which management has identified as critical to future growth. Quarterly updates on newer products like Winrevair and Welireg will indicate whether the portfolio strategy is gaining traction. Finally, watch for regulatory milestones on TERN-701 and other acquired assets to assess whether Merck's deal-making discipline translates into commercial success. Any shifts in guidance around the Keytruda patent cliff will be closely scrutinized.

This article was generated by Quantli AI using publicly available news sources.